ClinicalTrials.gg
TerminatedNCT00267280Updated Feb 17, 2012

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

A Phase 3 interventional study of torcetrapib/atorvastatin and simvastatin in Hyperlipidemia, Dyslipidemia and Hypercholesterolemia, sponsored by Pfizer. Terminated at 51 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-17.

Primary conditionHypercholesterolemiaRegistry: HyperlipidemiasReclassifiedWhy we changed it
Registry
Hyperlipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Hyperlipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
16th of 75
640 · median 148
Started
2006
with 1 other
Phase 3
31 of 77
none open now
Registered
14th of 77
by date

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 16th largest by enrollment of the 75 interventional ones that give a count, is one of 2 that started in 2006, is one of 31 in phase 3, and was the 14th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.

Read the detailed description

For additional information please call: 1-800-718-1021

03

Conditions studied

  • Hyperlipidemia
  • Dyslipidemia
  • Hypercholesterolemia

Browse trials for

04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 640 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hyperlipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • eligible for statin treatment for LDL cholesterol by NCEP guidelines

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
  • Subjects with significant liver or kidney disease or significant heart failure.
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
640 participants

Interventions

07

What researchers measure

Primary outcomes

  1. Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.

Secondary outcomes

  1. Changes in other lipid parameters and other biomarkers.

08

Study locations

51 sites
  • Pfizer Investigational Site
    Birmingham, Alabama, United States
  • Pfizer Investigational Site
    Mesa, Arizona, United States
  • Pfizer Investigational Site
    Alhambra, California, United States
  • Pfizer Investigational Site
    Inglewood, California, United States
  • Pfizer Investigational Site
    Los Angeles, California, United States
  • Pfizer Investigational Site
    Santa Ana, California, United States
  • Pfizer Investigational Site
    Wilmington, Delaware, United States
  • Pfizer Investigational Site
    Fort Lauderdale, Florida, United States
  • Pfizer Investigational Site
    Hollywood, Florida, United States
  • Pfizer Investigational Site
    Jacksonville, Florida, United States
  • Pfizer Investigational Site
    Merritt Island, Florida, United States
  • Pfizer Investigational Site
    Pensacola, Florida, United States
  • Pfizer Investigational Site
    Vero Beach, Florida, United States
  • Pfizer Investigational Site
    Winter Park, Florida, United States
  • Pfizer Investigational Site
    Atlanta, Georgia, United States
  • Pfizer Investigational Site
    Conyers, Georgia, United States
  • Pfizer Investigational Site
    Woodstock, Georgia, United States
  • Pfizer Investigational Site
    Hinsdale, Illinois, United States
  • Pfizer Investigational Site
    La Grange, Illinois, United States
  • Pfizer Investigational Site
    Park Ridge, Illinois, United States
  • Pfizer Investigational Site
    Springfield, Illinois, United States
  • Pfizer Investigational Site
    Kansas City, Kansas, United States
  • Pfizer Investigational Site
    Lexington, Kentucky, United States
  • Pfizer Investigational Site
    Baltimore, Maryland, United States
  • Pfizer Investigational Site
    Bethesda, Maryland, United States
  • Pfizer Investigational Site
    Elkton, Maryland, United States
  • Pfizer Investigational Site
    Flint, Michigan, United States
  • Pfizer Investigational Site
    Springfield, Missouri, United States
  • Pfizer Investigational Site
    Lawrenceville, New Jersey, United States
  • Pfizer Investigational Site
    Albany, New York, United States
  • Pfizer Investigational Site
    Seaford, New York, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio, United States
  • Pfizer Investigational Site
    Mansfield, Ohio, United States
  • Pfizer Investigational Site
    Hillsboro, Oregon, United States
  • Pfizer Investigational Site
    Beaver, Pennsylvania, United States
  • Pfizer Investigational Site
    Flourtown, Pennsylvania, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania, United States
  • Pfizer Investigational Site
    Yardley, Pennsylvania, United States
  • Pfizer Investigational Site
    Greenville, South Carolina, United States
  • Pfizer Investigational Site
    Collierville, Tennessee, United States
  • Pfizer Investigational Site
    Kingsport, Tennessee, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee, United States
  • Pfizer Investigational Site
    North Richland Hills, Texas, United States
  • Pfizer Investigational Site
    Spring, Texas, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah, United States
  • Pfizer Investigational Site
    West Jordan, Utah, United States
  • Pfizer Investigational Site
    Richmond, Virginia, United States
  • Pfizer Investigational Site
    Bellevue, Washington, United States
  • Pfizer Investigational Site
    Puyallup, Washington, United States
  • Pfizer Investigational Site
    Tacoma, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2005
First posted
Dec 20, 2005
Start
Jan 2006
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Results delay requested
Feb 15, 2012
Last update
Feb 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00267280
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 20, 2005
Start date
Jan 2006
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Feb 17, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin · Simvastatin

Start the discussion